DAVID GRANOVSKY

Posts Tagged ‘chemotherapy’

KILLER T-CELLS PRODUCED TO ATTACK DISEASE

In ALL ARTICLES, SCIENCE & STEM CELLS, STEM CELLS IN THE NEWS on January 14, 2013 at 9:00 am

cytotoxic-t-cells-300x219

Cells Grown By Japanese Researchers Kills Cancer

A team of researchers from both the University of Tokyo and the Riken Research Centre for Allergy and Immunology may have found a cure for HIV and Cancer. The research team was able to “extract live T-cells, the vital powerhouses of the human immune system, from patients, specifically targeting specialized cytotoxic T-cells which have the ability to recognize and attack signs of infection.  Researchers then converted the T-cells back to induced pluripotent stem cells (iPS) by exposing them to a group of compounds called the “Yamanaka factors,” in part so they could study the stem cells’ differentiation processes. Then the team reconverted the stem cells back into specialized disease-fighters, the T-cells known as “killer T-cells”or “killer T lymphocytes.” Among other critical findings, researchers discovered that the skin-cancer fighting T-cells remained capable of producing the crucial anti-tumor compound interferon.

“Stem cells can be grown at a much faster pace in a laboratory than in the human body, enabling researchers to create killer T lymphocytes that are—at least theoretically—ready for therapeutic human injection.”

“While the iPS cells did reconvert back into their original specializations, it’s unsure whether lab-grown cells will behave similarly to the immune system’s own disease-fighters when injected into the human body. Furthermore, the risk of rejection is high when cells from one patient are grown and converted for use in another.  Perhaps most importantly, it’s hard to predict whether cells that fight cancer in the lab will restrict their deadly effects to cancer cells in the body. Lead researcher Hiroshi Kawamoto, in a press release from the Riken Center, states, “the next step will be to test whether these T cells can selectively kill tumor cells but not other cells in the body.” It’s possible that lab-grown cells could attack normal, healthy human cells after therapeutic injection.  But medical and scientific experts remain cautiously optimistic.

“A lot of work needs to be done before we can think about clinical trials, but the initial data are promising.” Said Dr. Dusko Ilic, Senior Lecturer in Stem Cell Science, King’s College London.

The main challenge researchers face is the cost of producing large amounts of killer T lymphocytes safely. Numerous expensive confirmatory studies and trials will need to be conducted before the new therapy is approved for human use.

“The implications for the health of humankind, on the other hand, are immediate, and clear. If science has indeed provided a novel means of fighting our most persistent and deadly infections, untold amounts of suffering could be mitigated—and, ultimately, eradicated.”

http://www.usnewsuniversitydirectory.com/articles/cells-grown-by-japanese-researchers-kills-cancer_12861.aspx#.UPNh2GeAoTA

STEM CELL VACCINE IN DEVELOPMENT TO FIGHT CANCER

In ALL ARTICLES, SCIENCE & STEM CELLS, STEM CELLS IN THE NEWS on January 10, 2013 at 9:00 am

A1455614-07B7-A460-2C9B7A124BB3A86F_1

Cancer Stem Cell Vaccine in Development Shows Anti-tumor Effect

Philadelphia – Scientists may have discovered a new paradigm for immunotherapy against cancer by priming antibodies and T cells with cancer stem cells, according to a study published in Cancer Research, a journal of the American Association for Cancer Research.”

“This is a major breakthrough in immunotherapy research because we were able to use purified cancer stem cells to generate a vaccine, which strengthened the potency of antibodies and T cells that selectively targeted cancer stem cells.  We found that these enriched cancer stem cells were immunogenic and far more effective as an antigen source compared with the unselected tumor cells normally used in previous immunotherapy trials. The mechanistic investigations found that when antibodies were primed with cancer stem cells, they were capable of targeting cancer stem cells and conferring anti-tumor immunity.”

–          Qiao Li, Ph.D., a research assistant professor, department of surgery, University of Michigan.

imgname--threeparent_embryo---50226711--images--IVF_egg

The researchers also found that cytotoxic T lymphocytes harvested from cancer stem cell-vaccinated hosts were capable of killing cancer stem cells in vitro.”

http://www.aacr.org/home/public–media/aacr-press-releases.aspx?d=2744

Journal Reference:  Cancer Stem Cell Vaccination Confers Significant Antitumor Immunity. Cancer Research, 2012; 72 (7): 1853 DOI: 10.1158/0008-5472.CAN-11-1400

New Hope for Baby Boomers with Leukemia and Lymphomia

In VICTORIES & SUCCESS STORIES on March 1, 2011 at 9:12 am

New Hope for Baby Boomers with Leukemia and Lymphomia

Loyola University Health System
2/17/2011

Newswise — MAYWOOD, Ill. — As the first baby boomers turn 65, Loyola University Hospital has begun offering stem cell transplants to leukemia and lymphoma patients who previously were too old to qualify.

Hospitals traditionally have not offered stem cell transplants to patients older than 60 due to potentially severe complications. But Loyola now offers this treatment to patients in their 60s and early 70s.

“A lot of seniors are taking very good care of themselves. They’re in excellent shape, even running marathons and half-marathons,” said Dr. Patrick Stiff, director of Loyola’s Cardinal Bernardin Cancer Center. “As they potentially could live another 15 or 20 years, we believe they are just as worthy of receiving transplants as people in their teens or 20s.”

The median age of patients who are diagnosed with leukemia is between 65 and 68. For patients older than 60 who have aggressive forms of leukemia and undergo conventional therapy, the five-year survival rate is less than 5 percent.
But six of the first seven plus-60 patients who have undergone umbilical cord blood stem cell transplants at Loyola have survived. “They’re doing much better than we anticipated,” Stiff said.

William Karris of Carol Stream, Il. was 65 when he received a cord blood transplant at Loyola for an aggressive form of chronic lymphocytic leukemia. Without the transplant, Karris was expected to live only about six months. The transplant was successful, and Karris now is in remission more than a year and a half after transplant. The chances of a relapse are less than 2 percent, Stiff said.
Karris now plans to go ahead with a delayed knee-replacement surgery, and then return to work as a Bellwood police officer. “I feel pretty good,” he said.

A stem cell transplant can be a grueling and risky procedure. The patient undergoes high-dose chemotherapy, and sometimes high-dose radiation, to kill cancer cells. The treatment also destroys the patient’s immune system cells. To compensate, the patient receives an infusion of donor stem cells, which develop into healthy immune cells.

In addition to the side effects of chemotherapy and radiation, a patient is at risk for severe infections until the new immune system takes hold. And once established, the new immune system can attack the patient’s own body, a condition called graft-vs.-host disease. In such cases, the patient receives drugs to suppress the immune system, which in turn can increase the risk of infections.

Donor cells can come from a donor’s bone marrow or from a newborn’s umbilical cord blood. Stiff said cord blood transplants are easier on elderly patients than bone marrow transplants. Less than 10 percent of cord blood transplant patients experience significant graft-vs.-host disease, compared with about 50 percent of patients who receive bone marrow transplants.

Loyola has treated more than 3,000 patients with stem cell transplants, more than any other center in Illinois, and has one of the largest unrelated donor transplant programs in the world. Loyola physicians are currently focusing on umbilical cord blood transplants and have a number of novel therapies available for patients with leukemia, lymphoma and multiple myeloma who otherwise can not find a donor elsewhere.

Loyola has performed more than 90 cord blood transplants, and a new study has shown that a center’s experience is indeed an important factor in patient outcomes. Researchers examined records of 514 cord blood transplant patients in North America and Europe. They found that, 100 days after the transplant, the mortality rate was more than twice as high at centers with limited experience (fewer than 10 transplants). The study is published in the January, 2011 issue of the journal Bone Marrow Transplantation.

Bio-Matrix Scientific Group Inc. :: NIH News Confirms Trend in Stem Cell ‘Storage’ Facilities, says CEO of San Diego-based Bio-Matrix Scientific Group

In ALL ARTICLES, STEM CELLS IN THE NEWS on March 27, 2009 at 3:36 pm

blood-platelets-stem-cell

NIH News Confirms Trend in Stem Cell ‘Storage’ Facilities, says CEO of San Diego-based Bio-Matrix Scientific Group

SAN DIEGO, March 26 /PRNewswire-FirstCall/ — David Koos, Chairman and CEO of San Diego-based Bio-Matrix Scientific Group, Inc. (OTCBulletinBoard: BMSN) announced today that the important discovery reported on Wednesday, March 25 by researchers at the National Institutes of Health (NIH; http://www.nih.gov), which has implications for Leukemia treatment and artificially culturing blood cells, validates a new direction for stem cell “storage” facilities that meet rigid state and federal regulatory requirements. The researchers deciphered a key sequence of events governing whether the stem cells that produce red and white blood cells remain anchored to the bone marrow, or migrate into the circulatory system – an important discovery that will advance understanding of how blood cells and immune cells are generated.

“The findings of NIH researchers have implications for culturing infection-fighting immune cells outside the body, where they could be temporarily held in storage during chemotherapy and other treatments which suppress the immune system. This discovery confirms a new trend for commercial stem cell storage facilities for research and treatment of diseases, and their important role in public and private stem cell research efforts now and into the future,” said Koos.

via Bio-Matrix Scientific Group Inc. :: NIH News Confirms Trend in Stem Cell ‘Storage’ Facilities, says CEO of San Diego-based Bio-Matrix Scientific Group.

A STEM CELL… INSURANCE MIRACLE?

In ALL ARTICLES, STEM CELLS IN THE NEWS, VICTORIES & SUCCESS STORIES on February 9, 2009 at 12:36 am

A 3 year old boy is getting a repair stem cell transplant!

This is not an historic medical event…this barely registers as news.  Doctors have been using repair stem cells in order to prepare patient’s bodies for the ravages of high-dose chemotherapy for decades.

What is a miracle is that an insurance company is actually willing to pay for SOME of it!

A STEM CELL....INSURANCE MIRACLE?

Feb 8 2009 1:40PM -KXNewsTeam -AP-SDInsurance Stalemate,0160

SIOUX FALLS, S.D. (AP) A 3-year-old South Dakota boy whose brain tumor treatment had been in question because of an insurance dispute is to begin chemotherapy in Minnesota on Tuesday.

Cooper Urbaniak (ur-BAN’-ee-ak) is to be admitted to the University of Minnesota Medical Center to begin high-dose chemotherapy and a stem cell transplant.

The family’s insurance provider initially declared the procedure experimental and refused to pay for it. But under an agreement reached last month between Sanford Health Plan and the university, Sanford will pay for the chemotherapy and pay a discounted rate on the stem cell transplant.

The boy’s father, Joe Urbaniak, says his son will undergo eight days of chemotherapy treatments followed by a day of rest. Doctors then will give him back the stem cells they harvested earlier this fall.

The family is from Hereford, which is near Sturgis in western South Dakota.

By AP Writer Dirk Lammers (Copyright 2009 by The Associated Press. All Rights Reserved.) APNP 02-08-09 1330CST |

via 3yearold boy to begin chemo, stem cell treatment | KXNet.com North Dakota News.

%d bloggers like this: